[go: up one dir, main page]

NO983141L - Antigene peptider - Google Patents

Antigene peptider

Info

Publication number
NO983141L
NO983141L NO983141A NO983141A NO983141L NO 983141 L NO983141 L NO 983141L NO 983141 A NO983141 A NO 983141A NO 983141 A NO983141 A NO 983141A NO 983141 L NO983141 L NO 983141L
Authority
NO
Norway
Prior art keywords
antigenic peptides
antigenic
peptides
Prior art date
Application number
NO983141A
Other languages
English (en)
Other versions
NO313834B1 (no
Inventor
Gustav Gaudernack
Jon Amund Eriksen
Marianne Klemp Gjertsen
Mona Moeller
Ingvil Saeterdal
Stein Saeboee-Larsen
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19902234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO983141(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US09/743,281 priority Critical patent/US7030211B1/en
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Priority to NO19983141A priority patent/NO313834B1/no
Priority to DK03075681T priority patent/DK1362597T3/da
Priority to EP10183808.4A priority patent/EP2316476B1/en
Priority to CZ20010037A priority patent/CZ303215B6/cs
Priority to DE1999610580 priority patent/DE69910580T3/de
Priority to ES99928238T priority patent/ES2200526T5/es
Priority to AT99928238T priority patent/ATE247484T1/de
Priority to HU0104889A priority patent/HU230007B1/hu
Priority to PT03075681T priority patent/PT1362597E/pt
Priority to CA 2748996 priority patent/CA2748996A1/en
Priority to DK99928238T priority patent/DK1093381T4/da
Priority to AT03075681T priority patent/ATE458494T1/de
Priority to EP20030075681 priority patent/EP1362597B2/en
Priority to CA 2336743 priority patent/CA2336743C/en
Priority to CNB998099546A priority patent/CN100376290C/zh
Priority to HK02100577.9A priority patent/HK1039068B/zh
Priority to PL345541A priority patent/PL203815B1/pl
Priority to EP99928238A priority patent/EP1093381B2/en
Priority to AU45340/99A priority patent/AU756094B2/en
Priority to DE69942072T priority patent/DE69942072D1/de
Priority to PT99928238T priority patent/PT1093381E/pt
Priority to ES03075681.1T priority patent/ES2341170T5/es
Priority to PCT/NO1999/000220 priority patent/WO2000002581A1/en
Priority to EP10154215.7A priority patent/EP2258383B1/en
Priority to JP2000558840A priority patent/JP4618657B2/ja
Priority to ARP990103374 priority patent/AR020601A1/es
Priority to TW88115173A priority patent/TWI261617B/zh
Publication of NO983141L publication Critical patent/NO983141L/no
Publication of NO313834B1 publication Critical patent/NO313834B1/no
Priority to US11/332,378 priority patent/US7794723B2/en
Priority to CY101100364T priority patent/CY1109978T1/el
Priority to ARP100102596 priority patent/AR077576A2/es
Priority to JP2010177870A priority patent/JP5491315B2/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO19983141A 1998-07-08 1998-07-08 Telomeraseprotein eller -peptider, nukleinsyresekvenser som koder for disse, farmasöytiske sammensetninger inneholdende disseog fremgangsmÕter for Õ fremstille slike farmasöytiskesammensetninger til profylakse mot og behandling av kreft, samt NO313834B1 (no)

Priority Applications (32)

Application Number Priority Date Filing Date Title
US09/743,281 US7030211B1 (en) 1998-07-08 1990-06-30 Antigenic peptides derived from telomerase
NO19983141A NO313834B1 (no) 1998-07-08 1998-07-08 Telomeraseprotein eller -peptider, nukleinsyresekvenser som koder for disse, farmasöytiske sammensetninger inneholdende disseog fremgangsmÕter for Õ fremstille slike farmasöytiskesammensetninger til profylakse mot og behandling av kreft, samt
JP2000558840A JP4618657B2 (ja) 1998-07-08 1999-06-30 テロメラーゼ由来抗原ペプチド
HK02100577.9A HK1039068B (zh) 1998-07-08 1999-06-30 来自端粒酶的抗原性肽
PL345541A PL203815B1 (pl) 1998-07-08 1999-06-30 Zastosowanie peptydu telomerazy, zastosowanie kwasu nukleinowego, sposób wytwarzania limfocytów T, specyficzny wobec telomerazy limfocyt T, kompozycja farmaceutyczna, zastosowanie kombinacji peptydu telomerazy i peptydu zdolnego do indukowania odpowiedzi komórek T na onkogen lub zmutowane białko lub peptyd supresji nowotworów
CZ20010037A CZ303215B6 (cs) 1998-07-08 1999-06-30 Antigenní peptidy odvozené od telomerázy
DE1999610580 DE69910580T3 (de) 1998-07-08 1999-06-30 Von der telomerase abgeleitete antigene peptide
ES99928238T ES2200526T5 (es) 1998-07-08 1999-06-30 Peptidos antigenicos derivados de telomerasa.
AT99928238T ATE247484T1 (de) 1998-07-08 1999-06-30 Von der telomerase abgeleitete antigene peptide
HU0104889A HU230007B1 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
PT03075681T PT1362597E (pt) 1998-07-08 1999-06-30 Péptidos antigénicos derivados de telomerase
CA 2748996 CA2748996A1 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
DK99928238T DK1093381T4 (da) 1998-07-08 1999-06-30 Antigene peptider afledt fra teleromerase
AT03075681T ATE458494T1 (de) 1998-07-08 1999-06-30 Von der telomerase abgeleitete antigene peptide
EP20030075681 EP1362597B2 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
CA 2336743 CA2336743C (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
CNB998099546A CN100376290C (zh) 1998-07-08 1999-06-30 来自端粒酶的抗原性肽
DK03075681T DK1362597T3 (da) 1998-07-08 1999-06-30 Antigene peptider, der er afledt af telomerase
EP10183808.4A EP2316476B1 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
EP99928238A EP1093381B2 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
AU45340/99A AU756094B2 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
DE69942072T DE69942072D1 (de) 1998-07-08 1999-06-30 Von der Telomerase abgeleitete antigene Peptide
PT99928238T PT1093381E (pt) 1998-07-08 1999-06-30 Peptidos antigenicos derivados de telomerase
ES03075681.1T ES2341170T5 (es) 1998-07-08 1999-06-30 Péptidos antigénicos derivados de telomerasa
PCT/NO1999/000220 WO2000002581A1 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
EP10154215.7A EP2258383B1 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase
ARP990103374 AR020601A1 (es) 1998-07-08 1999-07-12 Peptidos o proteinas de telomerasa para el tratamiento o profilaxis del cancer, composiciones farmaceuticas que incluyen dichos peptidos o proteinas, uso de dicha composicion para la fabricacion de medicamentos y el metodo para generar linfocitos t capaces de reconocer y destruir celulas tumorales c
TW88115173A TWI261617B (en) 1998-07-08 1999-09-03 Antigenic peptides
US11/332,378 US7794723B2 (en) 1998-07-08 2006-01-17 Antigenic peptides derived from telomerase
CY101100364T CY1109978T1 (el) 1998-07-08 2010-04-23 Αντιγονικα πεπτιδια εξαγομενα απο τελομεραση
ARP100102596 AR077576A2 (es) 1998-07-08 2010-07-15 Un peptido de telomerasa y composiciones farmaceuticas para el tratamiento contra el cancer que comprenden tales peptidos
JP2010177870A JP5491315B2 (ja) 1998-07-08 2010-08-06 テロメラーゼ由来抗原ペプチド

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19983141A NO313834B1 (no) 1998-07-08 1998-07-08 Telomeraseprotein eller -peptider, nukleinsyresekvenser som koder for disse, farmasöytiske sammensetninger inneholdende disseog fremgangsmÕter for Õ fremstille slike farmasöytiskesammensetninger til profylakse mot og behandling av kreft, samt

Publications (2)

Publication Number Publication Date
NO983141L true NO983141L (no) 2000-01-10
NO313834B1 NO313834B1 (no) 2002-12-09

Family

ID=19902234

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19983141A NO313834B1 (no) 1998-07-08 1998-07-08 Telomeraseprotein eller -peptider, nukleinsyresekvenser som koder for disse, farmasöytiske sammensetninger inneholdende disseog fremgangsmÕter for Õ fremstille slike farmasöytiskesammensetninger til profylakse mot og behandling av kreft, samt

Country Status (20)

Country Link
US (2) US7030211B1 (no)
EP (4) EP1093381B2 (no)
JP (2) JP4618657B2 (no)
CN (1) CN100376290C (no)
AR (2) AR020601A1 (no)
AT (2) ATE247484T1 (no)
AU (1) AU756094B2 (no)
CA (2) CA2748996A1 (no)
CY (1) CY1109978T1 (no)
CZ (1) CZ303215B6 (no)
DE (2) DE69942072D1 (no)
DK (2) DK1362597T3 (no)
ES (2) ES2200526T5 (no)
HK (1) HK1039068B (no)
HU (1) HU230007B1 (no)
NO (1) NO313834B1 (no)
PL (1) PL203815B1 (no)
PT (2) PT1362597E (no)
TW (1) TWI261617B (no)
WO (1) WO2000002581A1 (no)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
EP1333094B1 (en) 1996-10-01 2012-04-04 Geron Corporation Human telomerase catalytic subunit
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
AU1331100A (en) 1998-10-29 2000-05-22 Dana-Farber Cancer Institute Cancer immunotheraphy and diagnosis using universal tumor associated antigens, including htert
CA2368967A1 (en) * 1999-04-09 2000-10-19 Biomira, Inc. Telomerase-specific cancer vaccine
EP1257284A4 (en) * 2000-02-15 2005-12-21 Univ California UNIVERSAL VACCINE AND METHOD OF TREATING CANCER USING TELOMERASE REVERSE TRANSCRIPTASE
JP2004527449A (ja) * 2000-02-15 2004-09-09 リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア テロメラーゼ逆転写酵素を用いる癌を治療するための万能ワクチンと方法
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
GB0031430D0 (en) 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
GB0112342D0 (en) * 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
CA2514288C (en) * 2003-03-05 2015-07-07 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
US10767167B2 (en) 2005-07-29 2020-09-08 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
AU2007215501A1 (en) * 2006-01-19 2007-08-23 The Regents Of The University Of California Human telomerase reverse transcriptase peptides
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
WO2008010010A1 (en) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
JP5207354B2 (ja) * 2008-03-12 2013-06-12 独立行政法人産業技術総合研究所 転写抑制ペプチド及びその遺伝子
US8828403B2 (en) * 2008-06-16 2014-09-09 Mediolanum Farmaceutici S.P.A. Anti-tumor immunotherapy
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
RU2642625C2 (ru) * 2009-11-10 2018-01-25 Аллегро Фармасьютикалс, Инк. Композиции и способы ингибирования клеточной адгезии или направленности диагностических или терапевтических агентов к rgd связывающим сайтам
LT2536830T (lt) * 2010-02-16 2019-11-11 Ultimovacs Asa Polipeptidai
FR2960542B1 (fr) 2010-05-27 2012-08-17 Esther Suzy Arlette Fellous Peptide en tant que medicament, en particulier pour le traitement du cancer
WO2012154894A2 (en) 2011-05-09 2012-11-15 Allegro Pharmaceuticals, Inc. Integrin receptor antagonists and their methods of use
KR20210025132A (ko) * 2012-05-11 2021-03-08 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
CN104661672B (zh) * 2012-05-11 2017-03-08 珍白斯凯尔有限公司 用于预防或治疗败血症的组合物
EP2847213B1 (en) * 2012-05-11 2018-01-03 KAEL-GemVax Co.,Ltd Anti-inflammatory peptides and composition comprising the same
US10967000B2 (en) * 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
TWI616530B (zh) * 2012-09-19 2018-03-01 傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物（一）
EP2899200B1 (en) 2012-09-19 2020-05-06 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
US9572900B2 (en) * 2012-09-19 2017-02-21 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
KR102038487B1 (ko) 2012-09-19 2019-10-30 주식회사 젬백스앤카엘 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물
EP2899199B1 (en) * 2012-09-19 2019-07-03 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
KR102166542B1 (ko) 2012-09-28 2020-10-16 주식회사 젬백스앤카엘 줄기세포 검출을 위한 텔로머라제 유래 펩티드 및 조영물질의 컨쥬게이트 및 이를 포함하는 조영제
CN102875657B (zh) * 2012-10-22 2014-04-09 南京工业大学 一种制备端粒酶多肽疫苗的方法
KR102093093B1 (ko) 2012-12-13 2020-03-25 주식회사 젬백스앤카엘 피부 노화 개선용 조성물
KR102106756B1 (ko) 2012-12-13 2020-05-06 주식회사 젬백스앤카엘 자외선에 의한 피부 손상 예방 또는 치료용 조성물
JP6474786B2 (ja) * 2013-04-19 2019-02-27 ジェムバックス アンド カエル カンパニー，リミティド 虚血性損傷の治療及び予防用の組成物
KR102275912B1 (ko) * 2013-05-03 2021-07-12 주식회사 젬백스앤카엘 Hsp 발현 억제 펩티드 및 이를 포함하는 조성물
AU2014275610B2 (en) 2013-06-07 2018-06-14 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
TWI539960B (zh) * 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
EP3020724A4 (en) * 2013-07-12 2017-01-18 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same
KR102204476B1 (ko) * 2013-08-14 2021-01-19 주식회사 젬백스앤카엘 다발성 경화증 치료 및 예방용 조성물
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
JP6382972B2 (ja) * 2013-10-23 2018-08-29 ジェムバックス アンド カエル カンパニー，リミティド 前立腺肥大治療用及びその予防用の組成物
KR102494803B1 (ko) * 2013-11-22 2023-02-06 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
KR102106757B1 (ko) * 2013-11-29 2020-05-06 주식회사 젬백스앤카엘 난소 동결 보존용 펩티드 및 이를 포함하는 조성물
KR102667428B1 (ko) * 2013-12-10 2024-05-21 주식회사 젬백스앤카엘 항산화 효과를 가지는 펩티드 및 이를 포함하는 조성물
CN105939723B (zh) * 2013-12-17 2020-02-28 珍白斯凯尔有限公司 前列腺癌治疗用组合物
KR102166549B1 (ko) 2014-01-10 2020-10-16 주식회사 젬백스앤카엘 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
JP6420459B2 (ja) * 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
WO2015170790A1 (ko) * 2014-05-09 2015-11-12 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
EP3138399B1 (en) 2014-04-30 2023-09-06 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
CN105504016B (zh) * 2014-05-29 2019-01-01 生工生物工程（上海）股份有限公司 一种治疗癌症的肽变体及其应用
KR102166543B1 (ko) 2014-06-02 2020-10-16 주식회사 젬백스앤카엘 켈로이드 억제용 조성물 및 그 억제 방법
KR102397510B1 (ko) * 2014-12-23 2022-05-13 주식회사 젬백스앤카엘 난소 기능 보존용 펩티드 및 이를 포함하는 조성물
KR102413243B1 (ko) * 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) * 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
ES2879641T3 (es) 2015-05-26 2021-11-22 Gemvax & Kael Co Ltd Octapéptidos antiinflamatorias, antifibróticos y cicatrizantes de heridas y las composiciones que los contienen
JP6923453B2 (ja) * 2015-07-02 2021-08-18 ジェムバックス アンド カエル カンパニー，リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
KR20170054310A (ko) * 2015-11-09 2017-05-17 주식회사 젬백스앤카엘 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법
JP7114481B2 (ja) 2016-04-07 2022-08-08 ジェムバックス アンド カエル カンパニー，リミティド テロメラーゼ活性の増加及びテロメアの延長の効能を有するペプチド、及びこれを含む組成物
MX374810B (es) 2017-01-06 2025-03-06 Eutilex Co Ltd Anticuerpos 4-1bb anti-humano y usos de los mismos
WO2018145020A1 (en) 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
EP3630131B1 (en) 2017-06-02 2022-08-31 Arizona Board of Regents on behalf of Arizona State University A method to create personalized canine cancer vaccines
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
US20230134801A1 (en) * 2020-04-17 2023-05-04 Lineage Cell Therapeutics, Inc. Mhc restricted immunogenic telomerase reverse transcriptase -specific peptides, their complex conjugates, and methods of using the same
WO2024253422A1 (ko) * 2023-06-08 2024-12-12 주식회사 젬백스앤카엘 Gv1001를 포함하는 치주질환 및 치주질환에 의한 장애의 예방 또는 치료용 조성물
WO2025123055A1 (en) * 2023-12-07 2025-06-12 Endevica Bio, Inc. Non-naturally occurring melanocortin analogs and associated methods for modulating weight gain

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
WO1995034638A1 (en) 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US5968506A (en) 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
PT880360E (pt) * 1996-02-12 2003-02-28 Ml Lab Plc Novos metodos de vacinacao e consequentes vacinas que compreendem um acido nucleico que codifica um primeiro epitopo e um peptido que contem um segundo epitopo
US5951976A (en) 1996-03-28 1999-09-14 Whitenead Institute For Biomedical Research Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
WO1998001493A1 (en) * 1996-07-08 1998-01-15 Jvs-Polymers Oy High impact strength biodegradable material
US5770422A (en) 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
EP1333094B1 (en) * 1996-10-01 2012-04-04 Geron Corporation Human telomerase catalytic subunit
US7390891B1 (en) * 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen

Also Published As

Publication number Publication date
AR020601A1 (es) 2002-05-22
PT1093381E (pt) 2004-01-30
ES2200526T3 (es) 2004-03-01
PT1362597E (pt) 2010-04-14
EP2316476A3 (en) 2011-09-14
HU230007B1 (en) 2015-04-28
NO313834B1 (no) 2002-12-09
DE69910580T2 (de) 2004-06-24
DK1362597T3 (da) 2010-06-14
DE69910580D1 (de) 2003-09-25
JP5491315B2 (ja) 2014-05-14
CN1313773A (zh) 2001-09-19
EP1362597B1 (en) 2010-02-24
EP2316476A2 (en) 2011-05-04
ATE458494T1 (de) 2010-03-15
CA2336743A1 (en) 2000-01-20
CN100376290C (zh) 2008-03-26
EP2258383A2 (en) 2010-12-08
EP1093381B1 (en) 2003-08-20
CA2336743C (en) 2011-10-11
EP1362597B2 (en) 2014-06-25
WO2000002581A1 (en) 2000-01-20
EP2316476B1 (en) 2015-11-25
PL203815B1 (pl) 2009-11-30
DK1093381T4 (da) 2009-09-21
EP2258383B1 (en) 2016-03-09
PL345541A1 (en) 2001-12-17
CA2748996A1 (en) 2000-01-20
ES2341170T5 (es) 2014-09-09
JP4618657B2 (ja) 2011-01-26
TWI261617B (en) 2006-09-11
CZ200137A3 (en) 2001-06-13
EP1093381A1 (en) 2001-04-25
ES2200526T5 (es) 2009-12-11
HK1039068A1 (zh) 2002-04-12
US7794723B2 (en) 2010-09-14
JP2010252810A (ja) 2010-11-11
AU756094B2 (en) 2003-01-02
CY1109978T1 (el) 2014-09-10
HUP0104889A3 (en) 2004-04-28
DE69942072D1 (de) 2010-04-08
US7030211B1 (en) 2006-04-18
CZ303215B6 (cs) 2012-05-30
US20060106196A1 (en) 2006-05-18
DK1093381T3 (da) 2003-09-08
AU4534099A (en) 2000-02-01
EP1093381B2 (en) 2009-07-22
AR077576A2 (es) 2011-09-07
ATE247484T1 (de) 2003-09-15
HUP0104889A2 (hu) 2002-04-29
DE69910580T3 (de) 2009-11-26
HK1039068B (zh) 2009-02-06
ES2341170T3 (es) 2010-06-16
JP2002520293A (ja) 2002-07-09
EP1362597A1 (en) 2003-11-19
EP2258383A3 (en) 2011-05-11

Similar Documents

Publication Publication Date Title
NO983141L (no) Antigene peptider
NO982097D0 (no) Peptider
NO982098D0 (no) Peptider
IS5375A (is) KAY-nýstárlegt ónæmisprótín
BR9711853A (pt) Vacinas
DK1042359T3 (da) k-Opioidreceptorpeptider
DE69826554D1 (de) Lehnstuhl
ATE394489T1 (de) Streptococcus antigene
NO985464D0 (no) Konsentrert antistoffpreparat
FI961350A7 (fi) Hapteenimerkityt peptidit
ATE347600T1 (de) Gruppe b-streptococcus antigene
NO985680L (no) Peptidderivater
NO983849D0 (no) Peptidderivater
BR9508433A (pt) Peptídeos
DE59807796D1 (de) Texturiermaschine
FI964363L (fi) Peptidejä
ATE295417T1 (de) Angiostatin-bindendes protein
TR199701666A3 (tr) Sismanliga karsi proteinler
DE59801799D1 (de) Reinigungsgerät
DE59803807D1 (de) Reinigungsgerät
PT1015447E (pt) Derivado piperidinilmetiloxazolidinona
NO20012283D0 (no) Koblede peptider
NO996412D0 (no) Antigene peptider
EP1151100A4 (en) TAU-CONOTOXIN PEPTIDE
DE69805402D1 (de) Lampenfassung

Legal Events

Date Code Title Description
MK1K Patent expired